Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01879319 · ClinicalTrials.gov registry record · Phase 3
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 164
- Enrollment target
NCT01879319 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 164 participants.
The verdict
NCT01879319, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 164 participants
- Enrollment target
Study Summary
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).
Interventions
- BIOLOGICAL Evolocumab AI/pen
- BIOLOGICAL Evolocumab AMD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2013-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01879319
The ClinicalTrials.gov registry entry for NCT01879319 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Evolocumab AI/pen is the first listed.
NCT01879319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01879319 about?
NCT01879319 is a clinical study titled "Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen". The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).
What is the current status of trial NCT01879319?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 164 participants. The study started on 2013-07-11.
What interventions are being tested in trial NCT01879319?
The interventions under investigation include: Evolocumab AI/pen (BIOLOGICAL), Evolocumab AMD (BIOLOGICAL).
Who is sponsoring clinical trial NCT01879319?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.